全文获取类型
收费全文 | 364篇 |
免费 | 13篇 |
国内免费 | 3篇 |
专业分类
妇产科学 | 11篇 |
基础医学 | 13篇 |
临床医学 | 18篇 |
内科学 | 32篇 |
神经病学 | 2篇 |
特种医学 | 26篇 |
外科学 | 8篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 14篇 |
肿瘤学 | 252篇 |
出版年
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 13篇 |
2012年 | 25篇 |
2011年 | 27篇 |
2010年 | 22篇 |
2009年 | 16篇 |
2008年 | 17篇 |
2007年 | 18篇 |
2006年 | 33篇 |
2005年 | 22篇 |
2004年 | 17篇 |
2003年 | 16篇 |
2002年 | 17篇 |
2001年 | 21篇 |
2000年 | 19篇 |
1999年 | 21篇 |
1998年 | 5篇 |
1997年 | 3篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 9篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
排序方式: 共有380条查询结果,搜索用时 31 毫秒
11.
Kakolyris SS Kouroussis C Koukourakis M Kalbakis K Mavroudis D Vardakis N Georgoulias V 《Anticancer research》2002,22(3):1891-1896
PURPOSE: CPT-11 and gemcitabine are both active agents against non-small cell lung cancer (NSCLC). We conducted a phase I study to determine the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of their combination in patients with previously treated advanced NSCLC. PATIENTS AND METHODS: Twenty-seven patients with histologically confirmed NSCLC, who had failed cisplatin-based front-line chemotherapy, were enrolled. The patients' median age was 56 years, 24 were male and 22 had a performance status (WHO) 0-1. Gemcitabine was administered on days 1 and 8, as a 30-minute i.v. infusion, at escalated doses ranging from 900 to 1200 mg/m2. CPT-11 was given over a 60-minute i.v. infusion on day 8 at escalated doses ranging from 200 to 350 mg/m2, following gemcitabine administration. The treatment was repeated every three weeks. RESULTS: The MTD was exceeded at dose-level 7 with CPT-11 350 mg/m2 and gemcitabine 1200 mg/m2, where all three enrolled patients presented DLTs (one patient grade 4 thrombocytopenia, one grade 3 diarrhea and one grade 3 asthenia). The recommended doses for future phase II studies are CPT-11 300 mg/m2 on day 8 and gemcitabine 1200 mg/m2 on days 1 and 8. A total of 107 treatment cycles were administered. Grade 3/4 neutropenia was observed in 13 (13%) cycles, febrile neutropenia in 3 (3%) and grade 3/4 thrombocytopenia in 2 (2%). Grade 2/3 diarrhea was seen in 6 (6%) cycles, grade 2/3 nausea and vomiting in 13 (13%) and grade 2/3 asthenia in 8 (8%). Other toxicities were mild. Among 23 patients evaluable for response, PR was achieved in one (4.5%), SD in 12 (52.5%) and PD in 10 (43%). CONCLUSION: The results of this phase I study clearly demonstrate that gemcitabine and CPT-11 can be efficiently combined in a low-toxicity regimen with doses equal or near monotherapy levels. Further studies are needed to evaluate the efficacy of this combination in both chemotherapy-naive and pre-treated patients with advanced NSCLC. 相似文献
12.
Vlachonikolis IG Aletra TJ Georgoulias V 《European journal of cancer (Oxford, England : 1990)》2002,38(4):574-577
The aim of this study was to present epidemiological results relating to malignant neoplasms of breast using primary data from the island of Crete, Greece, 1994-1995. The patients were all female residents of Crete with breast cancer first diagnosed during 1994 and 1995, 208 and 207 new incident cases, respectively. The data were collected and analysed by the Cancer Registry of Crete (CRC). Direct age-standardised rates (ASR) for incidence and cumulative risk (to age 75 years) were calculated for Crete as a whole. Standardised incidence ratios (SIR) were calculated for the 20 provinces (administrative regions); these were also smoothed using Bayesian methods. The ASR for incidence per 100000 person-years was 70.6. The truncated rate (age 40 years and above) was 153.7. The SIR for the 20 provinces showed no marked variations, with three exceptions, two of which had ratios higher than 1 and one lower. Bayesian smoothing of provincial incidence rates showed that throughout Crete, the risk of breast cancer shows considerable uniformity. The incidence rate of breast cancer on Crete is higher than that of Greece overall, and is comparable with other southern European countries. A possible explanation is that the published incidence for Greece may be an underestimation of the true rate. The small variability in breast cancer incidence within Crete probably reflects the homogeneity of the population and environmental and social conditions. 相似文献
13.
A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors 总被引:2,自引:0,他引:2
Kakolyris S Kouroussis C Koukourakis M Mavroudis D Marvroudis D Malas K Vardakis N Bozionelou V Kalbakis K Georgoulias V 《Oncology》2002,63(3):213-218
OBJECTIVES: Vinorelbine (V) and oxaliplatin (OX) have shown interesting activity in a wide range of solid tumors. A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of their combination in patients with refractory solid tumors. PATIENTS AND METHODS: Thirty-eight patients with histologically confirmed non-small-cell lung cancer, ovarian cancer and breast cancer who had failed at least one prior chemotherapy regimen were enrolled. The patients' median age was 60 years, 33 were female, and 27 had a performance status (WHO) of 0-1. V was administered on days 1 and 8 as a 1-hour intravenous infusion at escalated doses ranging from 20 to 27 mg/m2. OX was administered on days 1 and 8 at escalated doses ranging from 40 to 55 mg/m2, following V administration. Treatment was repeated every 3 weeks. RESULTS: At the dose of V 27 mg/m2 and OX 55 mg/m2 3 out of 6 enrolled patients presented DLTs (2 patients grade 4 neutropenia and 1 treatment delay at day 8), and, thus, the recommended MTD for future phase II studies are V 27 mg/m2 and OX 50 mg/m2. A total of 131 treatment cycles were administered. Grade 3/4 neutropenia complicated 23 (18%) treatment cycles. There was one septic death. The main nonhematologic toxicities were grade 2/3 nausea/vomiting (17 cycles; 13%), grade 2 neurotoxicity (6 cycles; 5%) and grade 2/3 asthenia (21 cycles; 16%). One CR (4%), 5 PR (20%) and 4 SD (16%) were observed amongst the 25 evaluable patients. All responses were observed in patients with ovarian and breast cancer. CONCLUSIONS: The results of this phase I study demonstrate that V and OX can be combined at clinically effective and relevant doses to be further evaluated in patients with breast and ovarian cancer. 相似文献
14.
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. 总被引:24,自引:0,他引:24
15.
Scintigraphy of stress fractures of the sesamoid bones 总被引:1,自引:0,他引:1
16.
Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study 总被引:3,自引:0,他引:3
Papadimitriou CA Moulopoulos LA Vlahos G Voulgaris Z Kiosses E Georgoulias N Gika D Diakomanolis E Michalas S Dimopoulos MA 《Cancer》2000,89(7):1547-1554
BACKGROUND: The combination of paclitaxel with cisplatin or carboplatin has become the preferred chemotherapy regimen in the treatment of epithelial ovarian carcinoma. Anthracyclines also have activity in this disease. We conducted a Phase II study by using the combination of paclitaxel, cisplatin, and epirubicin for the treatment of advanced ovarian carcinoma. METHODS: Forty consecutive patients with optimally (n = 7) or suboptimally (n = 33) debulked advanced ovarian carcinoma (International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV) were treated with paclitaxel, 135 mg/m(2), as a 3-hour intravenous infusion, cisplatin 75 mg/m(2) intravenously (i.v.), and epirubicin 50 mg/m(2) i.v. every 3 weeks on an outpatient basis. Granulocyte-colony stimulating factor was administered at a dose of 5 microg/kg/day on Days 5-9. RESULTS: Among 28 patients with measurable disease, 24 (86%%) achieved an objective response including 19 complete and 5 partial responses. Among 18 patients who underwent reassessment laparotomy, pathologic complete response was confirmed in 9 patients. At a minimum follow-up of 40 months, the median overall survival had not been reached whereas the median time to progression for all patients was 18.7 months. The median remission duration for women with measurable disease who responded to treatment was 14 months. The treatment was well tolerated without toxic deaths; the most common toxicity was Grade 3/4 neutropenia that occurred in 30% of patients. Significant neuropathy (Grade 2 or higher) developed in only 8% of patients. CONCLUSIONS: The combination of paclitaxel, cisplatin, and epirubicin is a well tolerated outpatient regimen with significant activity in the treatment of advanced epithelial ovarian carcinoma. 相似文献
17.
Kotsakis A Sarra E Peraki M Koukourakis M Apostolaki S Souglakos J Mavromanomakis E Vlachonikolis J Georgoulias V 《Cancer》2000,89(6):1380-1386
BACKGROUND: The quantitative abnormalities of the different peripheral blood lymphocyte subsets during docetaxel administration were prospectively studied. METHODS: Forty-six chemotherapy-naive patients with solid tumors were treated with docetaxel either in a 3 weekly (n = 33) or weekly (n = 13) schedule. Twenty patients with central nervous system (CNS) metastatic disease as the first clinical presentation of cancer and 35 patients with metastatic colorectal carcinoma treated with chemotherapy were enrolled as controls. The phenotype of peripheral blood lymphocytes was determined by indirect immunofluorescence using appropriate monoclonal antibodies and fluorescent-activated cell sorter analysis. RESULTS: After the administration of the first docetaxel cycle, the absolute number of peripheral blood lymphocytes (P < 0.005), CD3(+) (P < 0.01), CD4(+) (P < 0.01), CD8(+) (P < 0.01), and CD56(+) (P < 0. 01) but not CD20(+) (P < 0.3) cells was significantly decreased compared with the pretreatment values. Further treatment resulted in a further decrease of these lymphocyte subsets including CD20(+) cells (P < 0.01). Similarly, after the administration of the first weekly dose of docetaxel, the absolute number of total lymphocytes, CD3(+), CD4(+), and CD8(+) cells was decreased. The administration of the second weekly docetaxel dose resulted in a further decrease of CD56(+) (P = 0.012) and CD20(+) (P = 0.007) cells. The administration of either high dose corticosteroids in patients with CNS metastases or an irrelevant chemotherapy (CPT-11/5-FU) did not result in similar abnormalities. The discontinuation of docetaxel was associated with a recovery of CD3(+) and CD4(+) lymphocytes within a 3-month period. Eight (17%) patients developed nonneutropenic infections during docetaxel treatment. CONCLUSIONS: Docetaxel has an important but reversible nonspecific lymphopenic effect that seems to be associated with an increased risk for nonneutropenic infections. 相似文献
18.
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer 总被引:17,自引:0,他引:17
Koukourakis MI Giatromanolaki A Thorpe PE Brekken RA Sivridis E Kakolyris S Georgoulias V Gatter KC Harris AL 《Cancer research》2000,60(11):3088-3095
Vascular endothelial growth factor (VEGF) is an important angiogenic factor, linked to poor outcome in human malignancies including non-small cell lung carcinoma (NSCLC). We used the 11B5 monoclonal antibody recognizing the VEGF/KDR complex (R. A. Brekken et al., Cancer Res., 58: 1952-1959, 1998) to assess the VEGF expression in cancer cells and the VEGF/KDR activated microvessel density (aMVD) in early operable NSCLC. The JC70 anti-CD31 monoclonal antibody was used to assess the standard MVD (sMVD). The aMVD was significantly higher in the invading front of the tumors and in the normal lung adjacent to the tumors as compared with normal lung distant to the tumor or to inner tumor areas (P < 0.0002). The sMVD was higher in the normal lung and decreased from the invading front to inner tumor areas (P < 0.0001). However, the vascular activation (aMVD:sMVD) was 4-6 times higher in the tumor areas as compared with lung from normal individuals (36-58% versus 9%; P < 0.0001). Fibroblast 11B5 reactivity, noted in 25% of cases, correlated with high aMVD and sMVD in the inner tumor areas. Multivariate analysis showed that aMVD was the most potent and independent prognostic factor (P = 0.001; t-ratio, 3.28). It is concluded that intense VEGF/KDR angiogenic pathway activation is a tumor-specific feature in more than 50% of NSCLC cases and is associated with poor postoperative outcome. Clinical trials involving targeting of the VEGF/KDR-positive vasculature with specific antibodies, such as 11B5, are, therefore, encouraged. 相似文献
19.
Kouroussis C Samonis G Androulakis N Souglakos J Voloudaki A Dimopoulos MA Kotsakis T Kakolyris S Kalbakis K Georgoulias V 《American journal of clinical oncology》2000,23(3):309-313
Five cases of acute neutropenic enterocolitis complicating taxane-based chemotherapy are described. During a 34-month period, our department administered 4,600 courses of taxane-based (paclitaxel and docetaxel) chemotherapy to 800 cancer patients. Seven to 10 days postchemotherapy in five patients (0.1% of the given courses), neutropenic fever, abdominal pain, rebound tenderness, and grade II-IV diarrhea (bloody in two cases) developed. Two patients had oral candidiasis, and in two others septic shock developed. Computed tomography scans of the abdomen revealed in all patients thickening of the colon wall and pericolic edema, and a pericolic abscess was revealed in three of them. Both clinical and radiologic findings supported the diagnosis of acute neutropenic enterocolitis. All patients were successfully treated with broad-spectrum antibiotics and recombinant human granulocyte colony-stimulating factor. In conclusion, acute neutropenic enterocolitis is a severe complication of taxane-based chemotherapy. Early diagnosis and appropriate conservative treatment leads to complete recovery. Although rare, this infection is less often associated with other chemotherapeutic regimens. 相似文献
20.
High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy 总被引:2,自引:0,他引:2
Koukourakis MI Koukouraki S Giatromanolaki A Kakolyris S Georgoulias V Velidaki A Archimandritis S Karkavitsas NN 《Acta oncologica (Stockholm, Sweden)》2000,39(2):207-211
Sarcomas are radioresistant tumors, the only curative therapy being radical surgical resection. Stealth liposomal doxorubicin (Caelyx) is a novel drug formulation that allows prolonged circulation and high intratumoral concentration. This study investigates the concurrent use of radiotherapy with Caelyx in a cohort of 7 patients with locally advanced or recurrent sarcoma. Radiotherapy was given as a standard fractionation regimen to a total dose of 70 Gy. Caelyx was given as a 30-min infusion at a dose of 25 mg/m2 every 2 weeks. Scintigraphic imaging with Caelyx-99mTc-DTPA showed an increased (2.8 +/- 0.9 times higher) intratumoral drug accumulation compared to the surrounding healthy tissue. The regimen was well tolerated without any severe hematological or systemic toxicity. 'In field' radiation toxicity was not increased. Complete response was observed in 4/7 cases. It is concluded that combined chemo-radiotherapy with stealth liposomal doxorubicin for locally advanced sarcomas is feasible and promising, the benefit expected from the unique ability of the stealth liposomes to accumulate selectively in the tumoral tissue. 相似文献